Mineralys Therapeutics had its Relative Strength (RS) Rating upgraded from 70 to 76 Friday — a welcome improvement, but still short of the 80 or higher score you look for.
Can You Really Time The Stock Market?
This unique rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matched up against all other stocks.
History reveals that the market's biggest winners tend to have an RS Rating of above 80 in the early stages of their moves. See if Mineralys Therapeutics can continue to rebound and hit that benchmark.
Mineralys Therapeutics is trying to complete a cup with handle with a 16.90 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
Mineralys Therapeutics showed 0% EPS growth last quarter. Revenue increased 0%.
The company holds the No. 269 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
